Big Pharma’s Anti-Marijuana Stance Aims to Crush the Competition, Activists Say

‘As marijuana legalization swept the US in November, Arizona was alone in its rejection of legal weed. There, a pharmaceutical company called Insys was a major backer of the successful campaign to stop the state’s recreational cannabis measure, publicly arguing that pot businesses would be bad for public health and endanger children.
But to marijuana activists, the motive of Insys was clear – to squash the competition.
Confirming those suspicions, Insys has now received approval from the US Drug Enforcement Administration (DEA) to develop its own synthetic marijuana, the latest case of Big Pharma battling small cannabis growers.’
Read more: Big Pharma’s Anti-Marijuana Stance Aims to Crush the Competition, Activists Say